Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
-
Published:2021-03
Issue:
Volume:159
Page:103211
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Chong Lip Leong,
Soon Yu YangORCID,
Soekojo Cinnie YentiaORCID,
Ooi Melissa,
Chng Wee Joo,
de Mel Sanjay
Subject
Oncology,Hematology
Reference22 articles.
1. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study;Bahlis;Leukemia,2020
2. Treatment outcomes in patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation: systematic review and network meta-analysis;Cao;Clin. Lymphoma Myeloma Leuk.,2019
3. strmst2 and strmst2pw: new commands to compare survival curves using the restricted mean survival time;Cronin;Stata J.,2016
4. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;N. Engl. J. Med.,2016
5. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma;Facon;N. Engl. J. Med.,2019
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献